Lys158
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys158  -  TAK1 (human)

Site Information
ALIHRDLkPPNLLLV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 13310800

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 1 , 2 )
Relevant cell line - cell type - tissue:
HEK293T (epithelial) ( 1 , 2 ) , HeLa (cervical) ( 1 , 2 ) , MEF (fibroblast) ( 1 , 2 )

Upstream Regulation
Treatments:
IL-1b ( 2 ) , TNF ( 2 )

Downstream Regulation
Effects of modification on TAK1:
enzymatic activity, induced ( 2 ) , molecular association, regulation ( 2 )
Effects of modification on biological processes:
signaling pathway regulation ( 1 , 2 ) , transcription, induced ( 2 )
Induce interaction with:
IKKB (human) ( 2 ) , IKKG (human) ( 2 )

References 

1

Liang L, et al. (2013) TAK1 ubiquitination regulates doxorubicin-induced NF-κB activation. Cell Signal 25, 247-54
22981905   Curated Info

2

Fan Y, et al. (2010) Lysine 63-linked polyubiquitination of TAK1 at lysine 158 is required for tumor necrosis factor alpha- and interleukin-1beta-induced IKK/NF-kappaB and JNK/AP-1 activation. J Biol Chem 285, 5347-60
20038579   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.